- Home
- BUSE vs IMCR Comparison
BUSE vs IMCR Comparison
Compare BUSE & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUSE
- IMCR
- Stock Information
- Founded
- BUSE 1868
- IMCR 2008
- Country
- BUSE United States
- IMCR United Kingdom
- Employees
- BUSE N/A
- IMCR N/A
- Industry
- BUSE Major Banks
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BUSE Finance
- IMCR Health Care
- Exchange
- BUSE Nasdaq
- IMCR Nasdaq
- Market Cap
- BUSE 2.1B
- IMCR 1.7B
- IPO Year
- BUSE N/A
- IMCR 2021
- Fundamental
- Price
- BUSE $22.13
- IMCR $33.54
- Analyst Decision
- BUSE Buy
- IMCR Buy
- Analyst Count
- BUSE 7
- IMCR 8
- Target Price
- BUSE $27.43
- IMCR $57.00
- AVG Volume (30 Days)
- BUSE 515.4K
- IMCR 338.9K
- Earning Date
- BUSE 10-28-2025
- IMCR 11-05-2025
- Dividend Yield
- BUSE 4.52%
- IMCR N/A
- EPS Growth
- BUSE N/A
- IMCR N/A
- EPS
- BUSE 1.13
- IMCR N/A
- Revenue
- BUSE $498,525,000.00
- IMCR $356,145,000.00
- Revenue This Year
- BUSE $62.58
- IMCR $29.71
- Revenue Next Year
- BUSE $11.64
- IMCR $11.27
- P/E Ratio
- BUSE $19.63
- IMCR N/A
- Revenue Growth
- BUSE 16.77
- IMCR 26.78
- 52 Week Low
- BUSE $18.40
- IMCR $23.15
- 52 Week High
- BUSE $28.30
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- BUSE 35.41
- IMCR 48.36
- Support Level
- BUSE $22.46
- IMCR $31.37
- Resistance Level
- BUSE $23.96
- IMCR $35.03
- Average True Range (ATR)
- BUSE 0.63
- IMCR 1.45
- MACD
- BUSE -0.09
- IMCR -0.14
- Stochastic Oscillator
- BUSE 5.72
- IMCR 38.45
About BUSE First Busey Corporation
First Busey Corporation is a financial holding company, whose subsidiaries provides retail and commercial banking services, remittance processing, and offers financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech and Wealth Management. The banking segment generates a vast majority of its revenue.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.